top of page
Earth from Space

News

Your real-time pulse on the biomedical world, delivering concise updates on breakthrough discoveries, industry shifts, and emerging trends that are shaping the landscape of life sciences and healthcare innovation.

​​​

In today's fast-paced biomedical landscape, identifying promising assets, potential partners, and emerging technologies is crucial for companies looking to stay competitive and innovative. OniX Hub offers a groundbreaking solution to this challenge with its comprehensive Biotech and Startups Assets & Pipeline Dataset. This white paper explores how OniX Hub empowers companies to rapidly discover and evaluate early-stage assets, researchers, and potential collaborators, ultimately accelerating their R&D pathways.

Update:  The annual R&D spending in Asia, including countries such as Japan, South Korea, Singapore, China, India, Thailand, Indonesia, and Vietnam, exceeds $200 billion. A detailed breakdown of this expenditure is available for reference.

In a world where the US, UK, and EU federal governments collectively spend over $600 billion annually on R&D, the sheer volume of data generated daily is staggering. OniX stands at the forefront of harnessing this wealth of knowledge, serving as the premier research knowledge hub that standardizes preclinical data from universities, startups, biotech companies, accelerators, and incubators. By aggregating both public and proprietary data, OniX empowers strategic R&D and business development activities, accelerating the path from innovation to market.

Support for Tech Transfer Offices, Startup, Biotechs, Incubators, Accelerators, and Research Parks

OniX Hub is a platform designed to democratize access to a wealth of scientific and industry data, empowering startups, biotech companies, and research organizations to accelerate and de-risk their research and development efforts and to support their business development activities. OniX offers a startup fee to tech transfer offices, startups, and pre-seed biotech companies.

In a world where the US, UK, and EU federal governments collectively spend over $600 billion annually on R&D, the sheer volume of data generated daily is staggering. OniX stands at the forefront of harnessing this wealth of knowledge, serving as the premier research knowledge hub that standardizes preclinical data from universities, startups, biotech companies, accelerators, and incubators. By aggregating both public and proprietary data, OniX empowers strategic R&D and business development activities, accelerating the path from innovation to market.
 

The development of new drugs is a challenging process, involving substantial investments of time, resources, and expertise. However, one crucial stakeholder group is often overlooked or underutilized in this process: the patients themselves, along with their caregivers, families, and friends. These stakeholders possess a unique and invaluable perspective on the disease, its impact on daily life, and the unmet needs that drive the search for new therapeutic solutions. 
This white paper explores how generative AI can facilitate the critical role that patients play throughout the drug development journey, from idea and target identification to product launch and post-marketing surveillance. By embracing a patient-centric approach powered by generative AI, stakeholders can gain deeper insights into the real-world challenges faced by those living with the disease, identify key symptoms and priorities, and develop treatments that truly address their needs.
 

This white paper provides an overview of the key therapeutic focus areas of several major pharmaceutical companies, including Pfizer, AbbVie, UCB, and Takeda. It also highlights potential business development opportunities for companies interested in partnering.

The RAS pathway has long been a formidable challenge in cancer therapy, as mutations in RAS genes are implicated in driving the development and progression of numerous cancers, including lung, colorectal, pancreatic, and melanoma. Despite its significance, directly targeting mutant RAS proteins has proven to be a daunting task, often referred to as the "undruggable" target.

However, recent advancements in our understanding of the RAS signaling cascade have paved the way for innovative strategies to inhibit this critical pathway through various mechanisms of action (MoAs). OniX AI's comprehensive report on RAS pathway inhibitors provides an in-depth analysis of these diverse approaches, offering a powerful tool for researchers, drug developers, and industry professionals alike.
 

  • April 29. 2024 - The Gut-Brain Axis: A Frontier in Neuroscience and Medicine
    The gut-brain axis has emerged as a fascinating frontier in neuroscience and medicine. Mounting evidence suggests that the trillions of microbes residing in our gut can influence brain function and behavior through neural, endocrine, immune, and other biochemical pathways. This gut microbiome-brain communication has been implicated in numerous neurological disorders like depression and Alzheimer's disease. As a result, there is immense interest in exploring ways to modulate the gut microbiome composition and metabolism as a potential therapeutic strategy targeting these conditions.
     

  • April 5, 2024 - OniX AI: Revolutionizing Pipeline Analysis and Project Discovery – Partner with Us!- see T1D examples below

OniX is actively seeking partners to advance the development of its OniX AI, which not only conducts comprehensive pipeline analysis but also serves as a powerful tool for discovering new and innovative projects in the vast research landscape. Our overarching objective involves revolutionizing pipeline analysis and project discovery, empowering our partners to unlock insights and drive innovation. Furthermore, we aspire to integrate this functionality within the OniX hub, empowering our partners to generate analyses for any disease, target, or technology at their convenience.

T1D Preclinical  - T1D Clinical - T1D Biotech/Startup pipelines

​

​A comprehensive overview of patient engagement in biotech and pharmaceutical companies, emphasizing both traditional methods and innovative approaches. 

  • March 28,2024- Unveiling Parkinson's Disease:A  Glimpse into Ongoing Research with OniX AI 
    Parkinson's disease (PD) is a neurodegenerative disorder affecting millions globally. While the exact cause remains elusive, significant research efforts are underway to unravel the mechanisms behind PD and identify potential therapeutic targets. OniX AI, coupled with the OniX Hub, offers a powerful tool to navigate the vast amount of research data and pinpoint promising avenues for exploration. Let's delve into a few examples of ongoing PD research highlighted by OniX AI, showcasing its ability to identify trends and potential breakthroughs. 

​​

​OniX AI, a powerful tool within the OniX Hub, is designed to be your intelligent partner on the ever-evolving frontier of scientific discovery. It seamlessly processes and analyzes vast amounts of data, including research grants, publications, clinical trials, and patents. This summary offers a glimpse into the potential of OniX AI, using curated examples of Alzheimer's disease research grants.

​

Partnerships and engagement are essential cornerstones of the research enterprise, propelling innovation and progress. With the assistance of OniX Hub and OniX AI, the tasks of identifying partners, accessing Key Opinion Leaders (KOLs), and developing patient-centric therapeutics are made more accessible. By harnessing the power of data and AI, researchers and companies can navigate collaborations with confidence, accelerating the pace of discovery and ultimately improving patient outcomes.

​

Delve into our latest preclinical reports covering key areas.
Here's a glimpse into what our reports cover:
(i) Research Question: Our reports delve deep into pressing research questions, exploring the forefront of scientific inquiry and uncovering innovative solutions to complex medical challenges.
(ii) Stage of Development: We provide comprehensive insights into the developmental stage of various projects, from initial discovery to advanced preclinical phases, offering a roadmap for progress and potential breakthroughs.
(iii) Methods: With meticulous detail, we outline the methodologies employed in research, showcasing the rigorous scientific approach driving investigations and ensuring robust results.
(iv) Drug Development Opportunity: Perhaps most importantly, our reports identify promising opportunities for drug development, illuminating pathways towards impactful therapies that have the potential to transform patient care.

​​

  • March 21, 2024 -  UNVEILING INNOVATION: A deep dive into  OniX AI and OniX Hub

    • Example Network Graph to develop a landscape analysis and to find innovate projects related to Obesity

    • TIGIT: The ability of OniX AI to track the evolution of research areas by number of grants awarded over time, showcasing emerging trends and potential breakthroughs

    • University of Rochester, NY, USA: Researchers at the University Rochester are developing an Anti-Fouling Peptide-Nanoparticle Conjugates for the Delivery of siRNA to Fractures

    • Example of Japanese Biotech Progress: Transition of Heartseed from Academia (Keio University) to Biotech Company

  • March 11 2024 - Unlocking Intelligence for Tomorrow's Therapeutics: The Power of OniX Hub and OniX AI

​Biotech startups naturally accumulate competitive intelligence (CI) through various informal channels, such as attending conferences, interacting with industry peers, or reading market reports. Unfortunately, the challenge lies in the lack of organized management of this information, hindering the firm from fully optimizing these valuable resources and maximizing their potential value.

​

OniX demonstrates its AI capabilities by providing a preclinical and clinical landscape analysis of two rare skin diseases: Blau Syndrome and Hidradenitis suppurativa

​

bottom of page